Tradestie Institutional Equity Comparison Engine

ADPT vs MRNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MRNA Overall Edge

MRNA Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Moderna, Inc. Common Stock (MRNA) driven by superior Valuation, Momentum & Technical while ADPT counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, ADPT trades at N/M Forward P/E with -16.2% operating margin (-10.7% YoY revenue) versus MRNA at 23.0x Forward P/E and -80.8% operating margin (+29.2% YoY). In options structure, ADPT sits in BREAKOUT (36th %ile IV; Dealer Gamma Walls on Pro) against MRNA sits in CONSOLIDATION (64th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MRNA
ADPT N/M vs MRNA 23.0x Fwd P/E
Growth & Margin Winner ADPT
Op Margin -16.2% vs -80.8% ยท YoY -10.7% vs +29.2%
Momentum & Technical Winner MRNA
1Y +101.8% vs +731.6% ยท 52W Pos 81% vs 71%
Options & Structure Winner ADPT
BREAKOUT (36th %ile IV) vs CONSOLIDATION (64th %ile IV)
ADPT NASDAQ
Adaptive Biotechnologies Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$28.46
+2.12% 1D
Market Cap $4.7B
1M Return +18.83%
1Y Return +101.84%
Forward P/E N/M
Unified AI Score
43.2 / 100 HOLD
Tech 15.0 Fund 42.0 Flow 68.0 Mom 50.0
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$206.00
-4.31% 1D
Market Cap $90.4B
1M Return -9.21%
1Y Return +731.65%
Forward P/E 23.0x
Unified AI Score
46.6 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 67.0 Mom 46.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ADPT +101.84% MRNA +731.65% Spread: +629.81 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ADPT Revenue MRNA Revenue ADPT Op. Margin MRNA Op. Margin Margin Edge
FY2018 $60M $140M -89.4% -306.0% ADPT
FY2019 $90M $60M -92.1% -906.8% ADPT
FY2020 $100M $800M -155.3% -95.0% MRNA
FY2021 $150M $18.5B -135.4% 72.0% MRNA
FY2022 $190M $19.3B -108.0% 48.9% MRNA
FY2023 $170M $6.85B -133.3% -61.9% MRNA
FY2024 $180M $3.24B -90.8% -121.9% ADPT
FY2025 $280M $1.94B -20.6% -158.1% ADPT

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ADPT (4) vs MRNA (6)
Institutional Metric ADPT MRNA Criterion Row Winner
Market Capitalization Scale $4.7B $90.4B Larger Scale MRNA
Trailing P/E Ratio Valuation N/M 23.0x Lower Multiple MRNA
Forward P/E Ratio Valuation N/M 23.0x Lower Multiple MRNA
Revenue Growth (YoY) Growth -10.7% +29.2% Higher Growth MRNA
Operating Margin (TTM) Profitability -16.2% -80.8% Higher Margin ADPT
Net Profit Margin Profitability -23.7% -110.5% Higher Margin ADPT
Return on Equity (ROE) Capital Efficiency -36.4% -34.5% Higher ROE MRNA
52-Week Range Position Momentum 81% ($12โ€“$32) 71% ($22โ€“$281) Stronger Trend ADPT
Beta / 30D Volatility Risk Regime 1.71ฮฒ ยท 59% Vol 2.37ฮฒ ยท 100% Vol Lower Realized Risk ADPT
Unified Institutional Score Composite Signal 43.2 / 100 (HOLD) 46.6 / 100 (HOLD) Higher Composite MRNA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ADPT vs MRNA Buy Guide
ADPT BREAKOUT
70d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 36th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ADPT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
19d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 64th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ADPT nor MRNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.